BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 27389414)

  • 1. Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens.
    Laible M; Schlombs K; Kaiser K; Veltrup E; Herlein S; Lakis S; Stöhr R; Eidt S; Hartmann A; Wirtz RM; Sahin U
    BMC Cancer; 2016 Jul; 16():398. PubMed ID: 27389414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Robustness of biomarker determination in breast cancer by RT-qPCR: impact of tumor cell content, DCIS and non-neoplastic breast tissue.
    Hartmann K; Schlombs K; Laible M; Gürtler C; Schmidt M; Sahin U; Lehr HA
    Diagn Pathol; 2018 Oct; 13(1):83. PubMed ID: 30342538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®.
    Varga Z; Lebeau A; Bu H; Hartmann A; Penault-Llorca F; Guerini-Rocco E; Schraml P; Symmans F; Stoehr R; Teng X; Turzynski A; von Wasielewski R; Gürtler C; Laible M; Schlombs K; Joensuu H; Keller T; Sinn P; Sahin U; Bartlett J; Viale G
    Breast Cancer Res; 2017 May; 19(1):55. PubMed ID: 28490348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
    BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform.
    Wu NC; Wong W; Ho KE; Chu VC; Rizo A; Davenport S; Kelly D; Makar R; Jassem J; Duchnowska R; Biernat W; Radecka B; Fujita T; Klein JL; Stonecypher M; Ohta S; Juhl H; Weidler JM; Bates M; Press MF
    Breast Cancer Res Treat; 2018 Nov; 172(2):327-338. PubMed ID: 30120700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.
    Filipits M; Rudas M; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Lax SF; Halper S; Hulla W; Wu NC; Liu X; Weidler J; Bates M; Hlauschek D; Gnant M; Dubsky P
    ESMO Open; 2021 Aug; 6(4):100228. PubMed ID: 34371382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer.
    Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z
    Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.
    Wirtz RM; Sihto H; Isola J; Heikkilä P; Kellokumpu-Lehtinen PL; Auvinen P; Turpeenniemi-Hujanen T; Jyrkkiö S; Lakis S; Schlombs K; Laible M; Weber S; Eidt S; Sahin U; Joensuu H
    Breast Cancer Res Treat; 2016 Jun; 157(3):437-46. PubMed ID: 27220750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer.
    Gupta S; Mani NR; Carvajal-Hausdorf DE; Bossuyt V; Ho K; Weidler J; Wong W; Rhees B; Bates M; Rimm DL
    Lab Invest; 2018 Aug; 98(8):1076-1083. PubMed ID: 29858579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
    Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
    BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC).
    Breyer J; Wirtz RM; Laible M; Schlombs K; Erben P; Kriegmair MC; Stoehr R; Eidt S; Denzinger S; Burger M; Hartmann A; Otto W
    Virchows Arch; 2016 Nov; 469(5):547-552. PubMed ID: 27514658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The detection of ESR1/PGR/ERBB2 mRNA levels by RT-QPCR: a better approach for subtyping breast cancer and predicting prognosis.
    Du X; Li XQ; Li L; Xu YY; Feng YM
    Breast Cancer Res Treat; 2013 Feb; 138(1):59-67. PubMed ID: 23397283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative determination of estrogen receptor, progesterone receptor, and HER2 mRNA in formalin-fixed paraffin-embedded tissue--a new option for predictive biomarker assessment in breast cancer.
    Müller BM; Kronenwett R; Hennig G; Euting H; Weber K; Bohmann K; Weichert W; Altmann G; Roth C; Winzer KJ; Kristiansen G; Petry C; Dietel M; Denkert C
    Diagn Mol Pathol; 2011 Mar; 20(1):1-10. PubMed ID: 21326033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissues.
    Park S; Wang HY; Kim S; Ahn S; Lee D; Cho Y; Park KH; Jung D; Kim SI; Lee H
    Int J Clin Exp Pathol; 2014; 7(10):6752-9. PubMed ID: 25400755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast Cancer Subtype Classification Using 4-Plex Droplet Digital PCR.
    Chen W; Zheng J; Wu C; Liu S; Chen Y; Liu X; Du J; Wang J
    Clin Chem; 2019 Aug; 65(8):1051-1059. PubMed ID: 31010819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens.
    Janeva S; Parris TZ; Nasic S; De Lara S; Larsson K; Audisio RA; Olofsson Bagge R; Kovács A
    BMC Cancer; 2021 Apr; 21(1):439. PubMed ID: 33879115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reliable PCR quantitation of estrogen, progesterone and ERBB2 receptor mRNA from formalin-fixed, paraffin-embedded tissue is independent of prior macro-dissection.
    Tramm T; Hennig G; Kyndi M; Alsner J; Sørensen FB; Myhre S; Sørlie T; Overgaard J
    Virchows Arch; 2013 Dec; 463(6):775-86. PubMed ID: 24100522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the Xpert Breast Cancer STRAT 4 Assay on the GeneXpert instrument to Assess Hormone Receptor, Ki67, and HER2 Gene Expression Status in Breast Cancer Tissue Samples.
    Sewanywa L; Hale M; Michelow P; Mayne E; Wiggill T
    Appl Immunohistochem Mol Morphol; 2023 Oct; 31(9):613-620. PubMed ID: 37800656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luminal A versus luminal B breast cancer: MammaTyper mRNA versus immunohistochemical subtyping with an emphasis on standardised Ki67 labelling-based or mitotic activity index-based proliferation assessment.
    Finsterbusch K; Decker T; van Diest PJ; Focke CM
    Histopathology; 2020 Apr; 76(5):650-660. PubMed ID: 31846096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist.
    Badr NM; Zaakouk M; Zhang Q; Kearns D; Kong A; Shaaban AM
    Histopathology; 2024 Apr; ():. PubMed ID: 38651302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.